Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States-Reference-Cited by-同舟云学术

Cost-effectiveness of once weekly carfilzomib 70 mg/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States

Published:2020-04-06 Issue:6 Volume:13 Page:687-696
ISSN:1747-4086
Container-title:Expert Review of Hematology
language:en
Short-container-title:Expert Review of Hematology

Author:

Kumar Shaji K.¹^ORCID,Majer Istvan²,Panjabi Sumeet³,Medhekar Rohan⁴,Campioni Marco⁴,Dimopoulos Meletios A.⁵^ORCID

Affiliation:

1. Division of Hematology, Mayo Clinic, Rochester, MN, USA

2. Global Health Economics, Amgen (Europe) GmbH, Rotkreuz, Switzerland

3. Global Health Economics, Amgen, South San Francisco, CA, USA

4. Global Health Economics, Amgen, Thousand Oaks, CA, USA

5. School of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece

Funder

Amgen (Europe) GmbH, Zug, Switzerland

Publisher

Informa UK Limited

Subject

Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474086.2020.1746639

Reference36 articles.

1. Multiple Myeloma

2. American Cancer Society. Key statistics about multiple myeloma; 2018 [cited 2018 Oct 23]. Available from: https://www.cancer.org/cancer/multiple-myeloma/about/key-statistics.html

3. Multiple myeloma

4. American Cancer Society. Signs and symptoms of multiple myeloma; 2018 [cited 2018 Oct 23]. Available from: https://www.cancer.org/cancer/multiple-myeloma/detection-diagnosis-staging/signs-symptoms.html

5. Durie BGM Concise review of the disease and treatment options. International Myeloma Foundation (2017 Edition) 2017 [cited 2017 Oct 17]. Available from: https://www.myeloma.org/sites/default/files/images/publications/UnderstandingPDF/concisereview.pdf

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review;Clinical Lymphoma Myeloma and Leukemia;2023-06

2. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS;Blood Cancer Journal;2023-03-07

3. A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma;Cancers;2021-11-09

4. Tumor microenvironment: a prospective target of natural alkaloids for cancer treatment;Cancer Cell International;2021-07-20

5. Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies;Leukemia & Lymphoma;2020-10-28